Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.

Kojima Y, Kaga H, Hayashi S, Kitazawa T, Iimura Y, Ohno M, Yoshitsugu M, Fujiwara M, Hiyoshi T.

World J Diabetes. 2013 Feb 15;4(1):8-13. doi: 10.4239/wjd.v4.i1.8.

2.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
4.

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

Diabetes Care. 2000 Nov;23(11):1660-5.

5.

Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.

Tanimoto M, Kanazawa A, Hirose T, Yoshihara T, Kobayashi-Kimura S, Nakanishi R, Tosaka Y, Sasaki-Omote R, Kudo-Fujimaki K, Komiya K, Ikeda F, Someya Y, Mita T, Fujitani Y, Watada H.

J Diabetes Investig. 2015 Sep;6(5):560-6. doi: 10.1111/jdi.12338. Epub 2015 Mar 15.

6.
7.

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

Intern Med. 2007;46(22):1837-46. Epub 2007 Nov 16.

8.
9.
10.
12.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
13.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
14.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
15.

Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?

Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH.

Metabolism. 2000 Aug;49(8):1049-54.

PMID:
10954025
16.

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.

PMID:
15161773
17.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
18.

Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.

González-Clemente JM; Spanish Nateglinide Study Group.

Eur J Clin Invest. 2008 Mar;38(3):174-9. doi: 10.1111/j.1365-2362.2007.01918.x.

PMID:
18257780
19.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
20.

Supplemental Content

Support Center